| Sep 15 |
Insiders own 31% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 42% of the company
|
| Sep 10 |
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
|
| Sep 9 |
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
|
| Aug 23 |
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
|
| Aug 20 |
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?
|
| Aug 19 |
Top US Growth Companies With High Insider Ownership In August 2024
|
| Aug 19 |
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
|
| Aug 8 |
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
|
| Aug 8 |
ChromaDex Corporation 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 7 |
ChromaDex (CDXC) Reports Break-Even Earnings for Q2
|
